Business Wire

ESI-GROUP

Share
Enabling a World Premiere: 100% of the Development of a Vehicle Done in Virtual Reality

Regulatory News:

ESI Group (Paris:ESI), a global player in virtual prototyping for industries, participates in the successful development phase of the Nivus made by Volkswagen do Brazil: 100% digitally and virtually – a world premiere. The process began before the pandemic and was completed during the COVID-19 period, applying all the sanitary measures in place. Thanks to Virtual Prototyping/Digital Development (a change in product development), time was shortened in about 10 months and saved a few million euros in prototype production costs: Would it be a shift in the industry?

Making the right decision, quickly and 100% digitally
Usually, when a new vehicle is developed, time and physical prototypes are required both during the design and assembly preparation phases. In the case of the Nivus, launched in a live broadcast by Volkswagen do Brazil in June 2020 to around 60 countries, the whole conception of the vehicle was made 100% virtually. The state-of-the-art solution provided by ESI Group, based on its software IC.IDO was one of the tools used to design reviews and engineering decisions in different departments (product development, operations, quality, etc). This allowed Volkswagen to make informed decisions regarding the car’s conception. It provided the automotive company with the opportunity to save time (shortened the car’s development in about 10 months) and investment (for example, only in the Virtual Prototype Laboratory there was a 65% reduction of costs compared to previous projects).

Virtual reality also conserves tons of paper, in which specifications for each part of a car were previously detailed.

Long before Nivus physically existed, the vehicle was already available digitally in the engineering computers. Considering that building a physical prototype takes 19 weeks, in which only a single vehicle variant is possible. For this vehicle, nine virtual variants were produced, in much less time, which made it possible to anticipate more efficient assembly procedures, reducing the number of processes in the simulations and avoiding errors, since all parts were previously tested with digital tools.

"We designed 100% of the Nivus with digital processes using, among others, ESI’s technology without the need to assemble a single physical prototype. In addition, with the drastic reduction of the development time, this solution helps us to integrate all our different teams, from various department (design, engineering, marketing, production, etc) in the same decision-making process. It was a more efficient but also more collaborative process. " explains Francisvaldo Gomes Aires, Prototyping Development Manager at Volkswagen do Brazil.

Virtual reality: A huge benefit during COVID-19
ESI demonstrated that even when the design phase is impacted, in this case by COVID-19, it is possible to continue with the project, since it is no longer a question of relying solely on physical reality. This opens up the possibility of experiencing the future with digitalization and technology for the project benefit.

“It’s a shift in the industrial production. For the first time, all phases of a car release, before the effective production, has been fully made virtually making the production feasible during Covid-19 time. While allowing Volkswagen to take all its design and manufacturing decisions virtually, we helped them produce faster, cheaper and in a more sustainable way. This was possible due to a strong support of our local Brazilian team and a mutual collaboration between ESI Brazil and Volkswagen do Brazil. We all feel proud to be part of this world-premiere alongside with Volkswagen and its partners.” declares Andreas Renner, Volkswagen Global Account Manager – ESI Group.

About ESI Group
Founded in 1973, ESI Group is a leading innovator in Virtual Prototyping solutions and a global enabler of industrial transformation. Thanks to the company’s unique know-how in the physics of materials, it has developed and refined, over the last 45 years, advanced simulation capabilities. Having identified gaps in the traditional approach to Product Lifecycle Management (PLM), ESI has introduced a holistic methodology centered on industrial productivity and product performance throughout its entire lifecycle, i.e. Product Performance Lifecycle™, from engineering to manufacturing and in operation. Present in more than 20 countries, and in major industrial sectors, ESI employs 1200 high level specialists around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information, go to www.esi-group.com .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye